STAAR Surgical Company (STAA) Fair Value 2026

STAA · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.8 /10

32 fundamental signals · 3 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-08-28, STAAR Surgical Company (STAA) trades at $22.11, versus a $21.87 median fair value across its 3 active models — 1.1% below the current price. QOC: 6.8/10. Value Trap Risk: 24/100 (SAFE). 3/13 models active.

Key Facts

Ticker
STAA
Price
$22.11
Quality Score
6.8/10
Value Trap Risk
24/100
Models Active
3/13
Last Updated
Strength: Regime Cross-Sectional suggests +63.9% upside with 46% confidence
Risk: Majority of models suggest overvaluation

Is STAAR Surgical Company (STAA) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, STAAR Surgical Company (STAA) appears fairly valued as of : the median of 3 independent fair value estimates is $21.87, within 1.1% of the current price of $22.11. Estimates range from $2.52 to $36.23. STAA scores 6.8/10 on fundamental quality and 24/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. STAA’s -1.1% gap is narrower than that market norm, and the Medical Instruments & Supplies sector median is -29.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy STAAR Surgical Company Stock in 2026? →

What Fair Value Does Each Model Give STAA?

3 Intrinsic Value Models vs. Current Price ($22.11)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $2.52 -88.6%
Relative · Medium Conviction
 $36.23 +63.9%
Relative · Low Conviction
 $21.87 -1.1%

All Models Active

All 3 models are displayed above.

What Is STAA's Fair Value Range?

Spread across 3 independent models · $2.52 to $36.23

CirclFi's 3 active models place STAAR Surgical Company (STAA) between $2.52 and $36.23 per share, a spread of 154% of the median. The median of that range — $21.87 — is the fair value CirclFi publishes for STAA, against a current price of $22.11.

Low · EPVHigh · Regime Cross
$2.52median $21.87$36.23
Where the range comes from
Most bearish modelEarnings Power Value (EPV)$2.52
Most bullish modelRegime Cross-Sectional$36.23
Model agreement1 bullish · 1 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for STAA. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on STAA, not a CirclFi price target. How each model works →

What Is STAAR Surgical Company (STAA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, STAAR Surgical Company's intrinsic value is estimated at a median $21.87, showing conflicting signals at the current price of $22.11. While the median implied return is -1.1%, model disagreement is elevated with a gap of +152.5% between the most bullish and bearish estimates. The most optimistic model, Regime Cross, places fair value at $36.23 (+63.9%), while EPV — the most conservative — estimates $2.52 (-88.6%). This +152.5% gap reflects genuine analytical uncertainty about STAAR Surgical Company's intrinsic worth.

What Do the Models Say About STAA?

3 of 13 models are currently active for STAA. Of these, 1 model suggests upside while 2 models suggest overvaluation. Taken together, their median fair value for STAA is $21.87 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does STAA Rank in Medical Instruments & Supplies?

Among 56 Medical Instruments & Supplies stocks, STAA ranks #26 by Quality of Company score. CirclFi's QOC score of 6.8/10 evaluates 32 fundamental signals. A score of 6.8 indicates above-average quality.

See all Most Undervalued Medical Instruments & Supplies Stocks →

STAAR Surgical Company operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is STAA a Value Trap?

CirclFi's Value Trap algorithm assigns STAA a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for STAAR Surgical Company. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, STAAR Surgical Company is rated at 6.8/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +152.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every STAA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across STAA's 3 active models, average confidence is 40%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy STAAR Surgical Company Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

11 related Medical Instruments & Supplies stocks with 13-model coverage

BLFSBioLife Solutions, Inc.QOC 6.9OSUROraSure Technologies, Inc.QOC 6.8NXGLNEXGEL, Inc.QOC 7.0ANGOAngioDynamics, Inc.QOC 6.7SMTISanara MedTech Inc.QOC 7.1AVTRAvantor, Inc.QOC 6.5KMTSKestra Medical Technologies, Ltd.QOC 5.8ZJYLJin Medical International Ltd.QOC 2.9UTMDUtah Medical Products, Inc.QOC 8.2ISRGIntuitive Surgical, Inc.QOC 9.4RMDResMed Inc.QOC 9.4

Read investment analysis: BLFS · OSUR · NXGL · ANGO · SMTI · AVTR · KMTS · ZJYL · UTMD · ISRG · RMD

Which Other Stocks Have a Similar Quality Score to STAA?

7 companies across all industries closest to STAA’s Quality of Company score of 6.8/10.

CIZNCitizens Holding CompanyQOC 6.8ICCCImmuCell CorporationQOC 6.8OIO-I Glass, Inc.QOC 6.8MNTNMNTN, Inc.QOC 6.8BHICBioScience Health Innovations IQOC 6.8OCGNOcugen, Inc.QOC 6.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CIZN · ICCC · OI · MNTN · BHIC · OCGN · NVDA

Where Does STAA Sit in CirclFi's Medical Instruments & Supplies Rankings?

STAA is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About STAAR Surgical Company’s Valuation?

What is STAAR Surgical Company's intrinsic value in 2026?

CirclFi puts STAAR Surgical Company (STAA)'s intrinsic value at $21.87 — the median of 3 independent model estimates as of 2026-08-28, ranging from $2.52 to $36.23. The Quality of Company score is 6.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is STAA overvalued or undervalued right now?

At $22.11, 1 of 3 active models suggest STAA may be undervalued, while 2 indicate potential overvaluation. The median of all 3 fair value estimates is $21.87, within 1.1% of the current price of $22.11 — a consensus view that STAA is fairly valued. The assessment depends on which methodology best fits STAAR Surgical Company's business model in Medical Instruments & Supplies.

What does a Quality of Company score of 6.8 mean for STAA?

STAAR Surgical Company's QOC of 6.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on STAA?

CirclFi analyzes STAA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on STAA?

Of the 3 models currently active on STAA, Regime Cross-Sectional is the most bullish at $36.23 per share, and Earnings Power Value (EPV) is the most bearish at $2.52. CirclFi's published fair value for STAA is the median of that range, $21.87, not either extreme. The gap between the two ends equals 154% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is STAA a value trap in 2026?

STAAR Surgical Company's Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, STAAR Surgical Company (STAA) has a median fair value of $21.87 — within 1.1% of the current price of $22.11 — as of 2026-08-28.” Source: circlfi.com/stock/STAA/ · Methodology
Primary sources for this STAA valuation
  • Financial statements: STAAR Surgical Company 10-K and 10-Q filings on SEC EDGAR (CIK 0000718937) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for STAA as of ; valuations recomputed .